The prevalence of CD134+ cells was proven to be a prognostic factor in primary melanoma [38] and other cancers [39,40] and a biomarker that could predict the response to ipilimumab therapy [26] in previous studies. This evidence concerns the gene TNFRSF4 and melanoma.